IM Cannabis (NASDAQ: IMCC) is one of 43 public companies in the “Medicinals & botanicals” industry, but how does it compare to its competitors? We will compare IM Cannabis to related companies based on the strength of its risk, profitability, dividends, valuation, earnings, institutional ownership and analyst recommendations.
Earnings & Valuation
This table compares IM Cannabis and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|IM Cannabis||$11.86 million||-$21.42 million||-6.11|
|IM Cannabis Competitors||$220.78 million||-$89.53 million||-16.43|
Insider and Institutional Ownership
13.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 17.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 5.9% of IM Cannabis shares are owned by insiders. Comparatively, 29.2% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares IM Cannabis and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|IM Cannabis Competitors||-196.99%||-84.80%||-18.10%|
This is a breakdown of current ratings and recommmendations for IM Cannabis and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|IM Cannabis Competitors||221||604||580||12||2.27|
IM Cannabis presently has a consensus price target of $8.75, suggesting a potential upside of 160.42%. As a group, “Medicinals & botanicals” companies have a potential upside of 41.44%. Given IM Cannabis’ stronger consensus rating and higher probable upside, research analysts clearly believe IM Cannabis is more favorable than its competitors.
IM Cannabis beats its competitors on 8 of the 12 factors compared.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.